# Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

> **NCT06356597** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jing-yuan Fang, MD, Ph. D** · enrollment: 33 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Tislelizumab with Fruquintinib, Metronidazole

## Key facts

- **NCT ID:** NCT06356597
- **Lead sponsor:** Jing-yuan Fang, MD, Ph. D
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-19
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356597, "Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06356597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*